Patients should track not only scale weight but also measurements, how clothes fit, and energy levels to get a complete picture
Phase 3 TRIUMPH-4 results (68 weeks): 9mg dose: 26.4% average weight loss (29.1 kg) 12mg dose: 28.7% average weight loss (32.3 kg) Placebo: 2.1% average weight loss The 12mg retatrutide group lost an average of 71.2 pounds
From a dosing chart perspective, B12 addition does not change the tirzepatide dose itself
These results suggest Retatrutide could be explored as a novel anti-tumor treatment, especially for obesity-associated cancers, potentially through metabolic or immune pathways beyond its weight-loss effects
The study included 52 adult participants, consisting of 25 healthy individuals and 27 individuals with hypercholesterolemia 1
These broad estimates indicate the potential number of non-elderly adults who meet the clinical criteria for GLP-1 drugs, although employers and insurers may have more restrictive eligibility standards for coverage
